Based in Rockville, Maryland, OncoImmune is a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biopharmaceuticals for the treatment of cancer and autoimmune disease.
Founded in 2000 on the scientific discoveries of our founders, we have moved our lead product, CD24Fc, from a basic concept into clinical trials. CD24Fc has a novel mechanism of action that is applicable to a number of autoimmune diseases that has shown good safety and tolerability in a Phase I clinical trial in healthy volunteers. OncoImmune has completed a Phase II clinical trial of CD24Fc for the prophylactic treatment of acute Graft versus Host Disease (GvHD) for leukemia patients undergoing hematopoietic stem cell transplantation and in poised to launch a pivotal trial for the indication.
As part of global effort to confront COVID-19, OncoImmune has launched a Phase III clinical trial, SAC-COVID, to use CD24Fc for the treatment of severe and critical COVID-19 patients requiring oxygen support.
A clinical trial for OncoImmune’s second product, ONC-392, a next generation anti-CTLA-4 antibody, was initiated in July, 2020 and will assess the safety, pharmacokinetics, and efficacy of ONC-392 as a single agent in advanced solid tumors and in combination with anti-PD(L)1 standard of care in Non- Small Cell Lung Cancer.
In addition, OncoImmune has a rich pipeline of immunotherapy products that are moving through preclinical testing.